Elaiophylin Inhibits Tumorigenesis of Human Lung Adenocarcinoma by Inhibiting Mitophagy via Suppression of SIRT1/Nrf2 Signaling

Lung adenocarcinoma (LADC), the most common type of lung cancer, is still one of the most aggressive and rapidly fatal tumor types, even though achievements in new therapeutic approaches have been developed. Elaiophylin as a C2 symmetrically glycosylated 16 macrolides has been reported to be a late-...

Full description

Bibliographic Details
Main Authors: Jiali Ji, Ke Wang, Xinmin Meng, Hongqin Zhong, Xiyue Li, Hongqing Zhao, Guijuan Xie, Yunying Xie, Xun Wang, Xue Zhu
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/14/23/5812
_version_ 1797463546966048768
author Jiali Ji
Ke Wang
Xinmin Meng
Hongqin Zhong
Xiyue Li
Hongqing Zhao
Guijuan Xie
Yunying Xie
Xun Wang
Xue Zhu
author_facet Jiali Ji
Ke Wang
Xinmin Meng
Hongqin Zhong
Xiyue Li
Hongqing Zhao
Guijuan Xie
Yunying Xie
Xun Wang
Xue Zhu
author_sort Jiali Ji
collection DOAJ
description Lung adenocarcinoma (LADC), the most common type of lung cancer, is still one of the most aggressive and rapidly fatal tumor types, even though achievements in new therapeutic approaches have been developed. Elaiophylin as a C2 symmetrically glycosylated 16 macrolides has been reported to be a late-stage autophagy inhibitor with a potent anti-tumor effect on various cancers. This study investigated the anti-tumor effect of elaiophylin on human LADC for the first time in in vitro and in vivo models. The in vitro study in LADC A549 cells showed that elaiophylin significantly inhibited cell viability and induced cell apoptosis through the suppression of mitophagy and induction of cellular and mitochondrial oxidative stress. Proteomic analysis and molecular docking assay implicated that SIRT1 was likely the direct target of elaiophylin in A549 cells. Further mechanistic study verified that elaiophylin reduced Nrf2 deacetylation, expression, and transcriptional activity as well as cytoplasm translocation by downregulating SIRT1 expression and deacetylase activity. Additionally, SIRT1/Nrf2 activation could attenuate elaiophylin-induced mitophagy inhibition and oxidative stress. The in vivo study in the A549-xenograft mice model showed that the anti-tumor effect of elaiophylin was accompanied by the decreased expressions of SIRT1, Nrf2, Parkin, and PINK1. Thus, the present study reports that elaiophylin has potent anti-tumor properties in LADC, which effect is likely mediated through suppressing the SIRT1/Nrf2 signaling. In conclusion, elaiophylin may be a novel drug candidate for LADC and SIRT1 may be a new therapeutic target for such devastating malignancy.
first_indexed 2024-03-09T17:52:17Z
format Article
id doaj.art-6519b52fd3a24d67a2de8b97a8b7e03f
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-09T17:52:17Z
publishDate 2022-11-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-6519b52fd3a24d67a2de8b97a8b7e03f2023-11-24T10:39:05ZengMDPI AGCancers2072-66942022-11-011423581210.3390/cancers14235812Elaiophylin Inhibits Tumorigenesis of Human Lung Adenocarcinoma by Inhibiting Mitophagy via Suppression of SIRT1/Nrf2 SignalingJiali Ji0Ke Wang1Xinmin Meng2Hongqin Zhong3Xiyue Li4Hongqing Zhao5Guijuan Xie6Yunying Xie7Xun Wang8Xue Zhu9Department of Respiratory and Critical Care Medicine, The Affiliated Wuxi No. 2 People’s Hospital of Nanjing Medical University, Wuxi 214002, ChinaNational Health Commission (NHC) Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaDepartment of Clinical Laboratory, Cancer Hospital of Guangxi Medical University, Nanning 530021, ChinaDepartment of Respiratory and Critical Care Medicine, Wuxi Clinical College Affiliated to Nantong University, Wuxi 214002, ChinaDepartment of Respiratory and Critical Care Medicine, The Affiliated Wuxi No. 2 People’s Hospital of Nanjing Medical University, Wuxi 214002, ChinaDepartment of Respiratory and Critical Care Medicine, The Affiliated Wuxi No. 2 People’s Hospital of Nanjing Medical University, Wuxi 214002, ChinaDepartment of Respiratory and Critical Care Medicine, The Affiliated Wuxi No. 2 People’s Hospital of Nanjing Medical University, Wuxi 214002, ChinaInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, ChinaDepartment of Respiratory and Critical Care Medicine, The Affiliated Wuxi No. 2 People’s Hospital of Nanjing Medical University, Wuxi 214002, ChinaNational Health Commission (NHC) Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, ChinaLung adenocarcinoma (LADC), the most common type of lung cancer, is still one of the most aggressive and rapidly fatal tumor types, even though achievements in new therapeutic approaches have been developed. Elaiophylin as a C2 symmetrically glycosylated 16 macrolides has been reported to be a late-stage autophagy inhibitor with a potent anti-tumor effect on various cancers. This study investigated the anti-tumor effect of elaiophylin on human LADC for the first time in in vitro and in vivo models. The in vitro study in LADC A549 cells showed that elaiophylin significantly inhibited cell viability and induced cell apoptosis through the suppression of mitophagy and induction of cellular and mitochondrial oxidative stress. Proteomic analysis and molecular docking assay implicated that SIRT1 was likely the direct target of elaiophylin in A549 cells. Further mechanistic study verified that elaiophylin reduced Nrf2 deacetylation, expression, and transcriptional activity as well as cytoplasm translocation by downregulating SIRT1 expression and deacetylase activity. Additionally, SIRT1/Nrf2 activation could attenuate elaiophylin-induced mitophagy inhibition and oxidative stress. The in vivo study in the A549-xenograft mice model showed that the anti-tumor effect of elaiophylin was accompanied by the decreased expressions of SIRT1, Nrf2, Parkin, and PINK1. Thus, the present study reports that elaiophylin has potent anti-tumor properties in LADC, which effect is likely mediated through suppressing the SIRT1/Nrf2 signaling. In conclusion, elaiophylin may be a novel drug candidate for LADC and SIRT1 may be a new therapeutic target for such devastating malignancy.https://www.mdpi.com/2072-6694/14/23/5812lung adenocarcinomaelaiophylinmitophagyoxidative stressSIRT1/Nrf2 signaling
spellingShingle Jiali Ji
Ke Wang
Xinmin Meng
Hongqin Zhong
Xiyue Li
Hongqing Zhao
Guijuan Xie
Yunying Xie
Xun Wang
Xue Zhu
Elaiophylin Inhibits Tumorigenesis of Human Lung Adenocarcinoma by Inhibiting Mitophagy via Suppression of SIRT1/Nrf2 Signaling
Cancers
lung adenocarcinoma
elaiophylin
mitophagy
oxidative stress
SIRT1/Nrf2 signaling
title Elaiophylin Inhibits Tumorigenesis of Human Lung Adenocarcinoma by Inhibiting Mitophagy via Suppression of SIRT1/Nrf2 Signaling
title_full Elaiophylin Inhibits Tumorigenesis of Human Lung Adenocarcinoma by Inhibiting Mitophagy via Suppression of SIRT1/Nrf2 Signaling
title_fullStr Elaiophylin Inhibits Tumorigenesis of Human Lung Adenocarcinoma by Inhibiting Mitophagy via Suppression of SIRT1/Nrf2 Signaling
title_full_unstemmed Elaiophylin Inhibits Tumorigenesis of Human Lung Adenocarcinoma by Inhibiting Mitophagy via Suppression of SIRT1/Nrf2 Signaling
title_short Elaiophylin Inhibits Tumorigenesis of Human Lung Adenocarcinoma by Inhibiting Mitophagy via Suppression of SIRT1/Nrf2 Signaling
title_sort elaiophylin inhibits tumorigenesis of human lung adenocarcinoma by inhibiting mitophagy via suppression of sirt1 nrf2 signaling
topic lung adenocarcinoma
elaiophylin
mitophagy
oxidative stress
SIRT1/Nrf2 signaling
url https://www.mdpi.com/2072-6694/14/23/5812
work_keys_str_mv AT jialiji elaiophylininhibitstumorigenesisofhumanlungadenocarcinomabyinhibitingmitophagyviasuppressionofsirt1nrf2signaling
AT kewang elaiophylininhibitstumorigenesisofhumanlungadenocarcinomabyinhibitingmitophagyviasuppressionofsirt1nrf2signaling
AT xinminmeng elaiophylininhibitstumorigenesisofhumanlungadenocarcinomabyinhibitingmitophagyviasuppressionofsirt1nrf2signaling
AT hongqinzhong elaiophylininhibitstumorigenesisofhumanlungadenocarcinomabyinhibitingmitophagyviasuppressionofsirt1nrf2signaling
AT xiyueli elaiophylininhibitstumorigenesisofhumanlungadenocarcinomabyinhibitingmitophagyviasuppressionofsirt1nrf2signaling
AT hongqingzhao elaiophylininhibitstumorigenesisofhumanlungadenocarcinomabyinhibitingmitophagyviasuppressionofsirt1nrf2signaling
AT guijuanxie elaiophylininhibitstumorigenesisofhumanlungadenocarcinomabyinhibitingmitophagyviasuppressionofsirt1nrf2signaling
AT yunyingxie elaiophylininhibitstumorigenesisofhumanlungadenocarcinomabyinhibitingmitophagyviasuppressionofsirt1nrf2signaling
AT xunwang elaiophylininhibitstumorigenesisofhumanlungadenocarcinomabyinhibitingmitophagyviasuppressionofsirt1nrf2signaling
AT xuezhu elaiophylininhibitstumorigenesisofhumanlungadenocarcinomabyinhibitingmitophagyviasuppressionofsirt1nrf2signaling